Covid

Covid

460 bookmarks
Custom sorting
It's the virus, stupid.
It's the virus, stupid.
When the vaccines were first introduced in December 2020, the virus they were designed against was altogether different from what it is today. SARS-CoV-2 had little substantive functional evolution from late 2019 until we saw the Alpha variant in the first months of 2021. It was, in retrospect, an easy target with a fraction of the immune escape and transmissibility that we are dealing with now. Had the virus not subsequently evolved so profoundly, its containment would have been straightforward and we wouldn’t be talking about a pandemic right now in the present tense. Breakthrough and reinfections wouldn’t be commonplace. Population-level (“herd”) immunity would have been possible. The 95% efficacy of the mRNA vaccines against symptomatic infections, hospitalizations and deaths, exhibited waning in latter half of 2021, during the Delta wave, but was fully restored with a 3rd shot. Reinfections were less than 1%. We were prevailing over the virus.
·erictopol.substack.com·
It's the virus, stupid.
Novavax is here! Just not the silver bullet we need
Novavax is here! Just not the silver bullet we need
Yesterday, ACIP—CDC’s external scientific advisory board—unanimously voted to authorize the Novavax vaccine (called NVX-CoV2373) in the U.S. This was big news for the small, underdog Maryland company who had a long road to authorization. After rigorous clinical trials, FDA and CDC scientific meetings, and more than
·yourlocalepidemiologist.substack.com·
Novavax is here! Just not the silver bullet we need
Whose breath are you breathing?
Whose breath are you breathing?
How much of the air you're breathing is air someone else exhaled? And in the midst of a pandemic caused by an airborne virus, where are the riskiest places to be?
·rnz.co.nz·
Whose breath are you breathing?
How to Reduce Risk of Getting Long COVID
How to Reduce Risk of Getting Long COVID
This article was originally posted in the Montreal Gazette. There is still a great deal that is uncertain about the persistent symptoms that we have taken to calling long COVID. Why it happens, how common it is and how to treat it are all still somewhat unclear. But a research letter recently published in the Journal of the American Medical Association provides at least some hints on how we can prevent it. Up until now, there was ambiguity about whether vaccination prevented long COVID or not. Data from the U.S. Department of Veterans Affairs suggested that persistent symptoms were lower in vaccinated individuals, but not all the early data was entirely consistent. Part of the problem in studying long COVID is that different groups use different definitions. The U.S. Centers for Disease Control and Prevention defines it as symptoms that persist for four weeks after infection whereas, the World Health Organization uses three months after the onset of COVID infection. Depending on which definition you use, you can get very different estimates for how common long COVID actually is. The risk of long COVID is also going to differ depending on whether you consider people who were hospitalized for severe infections, people with only mild infections, or a combination of the two. When different studies use different methodologies, comparing them becomes an apples to oranges problem. The most recent data, from researchers in Milan, provides some useful information. Researchers analyzed health-care workers from nine medical centres in Italy and compared the COVID recovery of vaccinated and unvaccinated employees. Workers were being screened for COVID every one to two weeks, so virtually all cases would have been picked up. If mild cases were to go undiagnosed, that would provide a falsely elevated estimate of long-COVID risk. Researchers also limited their analysis to non-hospitalized COVID patients, which again guarded against overestimating the risk of long COVID by mixing together milder and more severe cases. Perhaps unsurprisingly, older patients and those with pre-existing medical conditions were more likely to have persistent symptoms one month after infection. That being said, I’ve anecdotally seen many younger patients with persistent symptoms, and it is important to remember that lower risk does not mean zero risk. Interestingly, the risk of long COVID did not differ significantly by wave, which argues against the notion that the newer variants are less likely to cause severe disease. What did make the largest difference was vaccination status. Getting two or three doses reduced the odds of developing long COVID by 75 and 85 per cent respectively. Receiving a single dose did not. Since the data was largely derived from infections that occurred in 2021, many health-care workers had only received two doses at that time. Intuitively, it seems logical that vaccination would reduce the risk of long COVID, and many of us assumed that would be the case. Vaccination reduces the severity of disease and also prevents infection. Despite what people say online, multiple studies have shown that vaccination with three doses plays an important role in preventing infection. While the vaccines are less protective against Omicron than they were against the Delta variant, three doses still reduced the odds of infection by 76 per cent. Many aspects of long COVID still defy simple answers. There is no clear diagnostic test or treatment; people have very different symptoms that may not all be due to the same cause. Symptoms do improve with time, but it is hard to predict who will improve and how long it will take. The one thing we can say with slightly more certainty is that vaccination seems to reduce the risk of persistent symptoms. Of course, the best way to avoid long COVID is not get COVID in the first place, and the vaccines can help with that, too. So can wearing a mask and just being careful. @DrLabos
·mcgill.ca·
How to Reduce Risk of Getting Long COVID
Masks for COVID: Updating the evidence
Masks for COVID: Updating the evidence
Notes taken whilst preparing a paper on mask efficacy from Nov to Jan 2022. My previous paper on this was written in April 2020 and published in the Proceedings of the National Academy of Science
·fast.ai·
Masks for COVID: Updating the evidence
Settling in for the long haul
Settling in for the long haul
A couple of tweets flicked across my screen in the past week or so from people I don’t know asking how, perhaps a year or two in, the knowledge settles across your shoulders that you’re not recover…
·crookedtimber.org·
Settling in for the long haul
Get Ready for the Forever Plague | The Tyee
Get Ready for the Forever Plague | The Tyee
Public health officials’ COVID complacency has opened the door to new illnesses and devastating long-term damage.
·thetyee.ca·
Get Ready for the Forever Plague | The Tyee
Actor Matt Ford describes what it's like to have monkeypox | Boing Boing
Actor Matt Ford describes what it's like to have monkeypox | Boing Boing
Matt Ford has monkeypox, and he wrote this article to tell you all what it’s like. And to explain exactly why you do not want it. In Matt’s words, “This is my experience, but it boils down to this:…
·boingboing.net·
Actor Matt Ford describes what it's like to have monkeypox | Boing Boing
Monkeypox Vaccine 101
Monkeypox Vaccine 101
Two days ago the CDC activated an Emergency Operations Center for our monkeypox (MPX) response
·yourlocalepidemiologist.substack.com·
Monkeypox Vaccine 101
The BA.5 story
The BA.5 story
The takeover by this Omicron sub-variant is not pretty
·erictopol.substack.com·
The BA.5 story
Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure
Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure
The Omicron, or Pango lineage B.1.1.529, variant of SARS-CoV-2 carries multiple spike mutations with high transmissibility and partial neutralizing antibody (nAb) escape. Vaccinated individuals show protection from severe disease, often attributed to ...
·science.org·
Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure
Zero-COVID and Free Speech
Zero-COVID and Free Speech
Zero-COVID is possible, but few of us in the West are willing to pay the costs; the exact same reasoning applies to free speech; in both cases China-lite is the worst possible strategy.
·stratechery.com·
Zero-COVID and Free Speech
Moderna says Omicron-containing booster outperforms current vaccine
Moderna says Omicron-containing booster outperforms current vaccine
Moderna said Wednesday that using a new version of its Covid-19 vaccine as a booster led to a superior antibody response against the Omicron variant compared to its current shot.
·statnews.com·
Moderna says Omicron-containing booster outperforms current vaccine